18 USD
+0.09 (+0.5%)
TBPH gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. While TBPH seems to be doing ok healthwise, there are quite some concerns on its profitability. TBPH has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year TBPH has reported negative net income.
TBPH had a positive operating cash flow in the past year.
In the past 5 years TBPH reported 4 times negative net income.
TBPH had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
TBPH's Return On Assets of 7.06% is amongst the best of the industry. TBPH outperforms 88.48% of its industry peers.
Looking at the Return On Equity, with a value of 12.61%, TBPH belongs to the top of the industry, outperforming 87.43% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.06% | ||
| ROE | 12.61% | ||
| ROIC | N/A |
ROA(3y)37.73%
ROA(5y)0.15%
ROE(3y)46.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TBPH has a better Profit Margin (36.53%) than 96.86% of its industry peers.
The Operating Margin and Gross Margin are not available for TBPH so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 36.53% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
TBPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TBPH has been increased compared to 1 year ago.
The number of shares outstanding for TBPH has been reduced compared to 5 years ago.
TBPH has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 0.73, we must say that TBPH is in the distress zone and has some risk of bankruptcy.
TBPH has a Altman-Z score (0.73) which is in line with its industry peers.
The Debt to FCF ratio of TBPH is 0.13, which is an excellent value as it means it would take TBPH, only 0.13 years of fcf income to pay off all of its debts.
TBPH has a Debt to FCF ratio of 0.13. This is amongst the best in the industry. TBPH outperforms 97.38% of its industry peers.
A Debt/Equity ratio of 0.14 indicates that TBPH is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.14, TBPH is in line with its industry, outperforming 47.64% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.14 | ||
| Debt/FCF | 0.13 | ||
| Altman-Z | 0.73 |
ROIC/WACCN/A
WACC9.34%
2.3 Liquidity
TBPH has a Current Ratio of 9.48. This indicates that TBPH is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of TBPH (9.48) is better than 78.53% of its industry peers.
TBPH has a Quick Ratio of 9.48. This indicates that TBPH is financially healthy and has no problem in meeting its short term obligations.
TBPH's Quick ratio of 9.48 is fine compared to the rest of the industry. TBPH outperforms 78.53% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.48 | ||
| Quick Ratio | 9.48 |
3. Growth
3.1 Past
TBPH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -10.53%.
The Revenue has grown by 27.12% in the past year. This is a very strong growth!
TBPH shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -2.59% yearly.
EPS 1Y (TTM)-10.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%126.92%
Revenue 1Y (TTM)27.12%
Revenue growth 3Y5.2%
Revenue growth 5Y-2.59%
Sales Q2Q%18.51%
3.2 Future
The Earnings Per Share is expected to grow by 29.13% on average over the next years. This is a very strong growth
TBPH is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 31.87% yearly.
EPS Next Y275.95%
EPS Next 2Y69.86%
EPS Next 3Y27.47%
EPS Next 5Y29.13%
Revenue Next Year71.87%
Revenue Next 2Y17.68%
Revenue Next 3Y24.7%
Revenue Next 5Y31.87%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
TBPH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 18.65, which indicates a rather expensive current valuation of TBPH.
76.44% of the companies in the same industry are more expensive than TBPH, based on the Price/Forward Earnings ratio.
TBPH is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 23.58, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 18.65 |
4.2 Price Multiples
97.91% of the companies in the same industry are more expensive than TBPH, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.75 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
TBPH's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
TBPH's earnings are expected to grow with 27.47% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y69.86%
EPS Next 3Y27.47%
5. Dividend
5.1 Amount
TBPH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:TBPH (12/18/2025, 11:46:14 AM)
18
+0.09 (+0.5%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners97.37%
Inst Owner Change5.17%
Ins Owners4.31%
Ins Owner Change-4.88%
Market Cap912.06M
Revenue(TTM)80.33M
Net Income(TTM)29.34M
Analysts80
Price Target27.25 (51.39%)
Short Float %11.53%
Short Ratio12.28
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-12.59%
Min EPS beat(2)-178.66%
Max EPS beat(2)153.48%
EPS beat(4)1
Avg EPS beat(4)-21.5%
Min EPS beat(4)-178.66%
Max EPS beat(4)153.48%
EPS beat(8)2
Avg EPS beat(8)-16.75%
EPS beat(12)4
Avg EPS beat(12)-14.07%
EPS beat(16)4
Avg EPS beat(16)-30.83%
Revenue beat(2)0
Avg Revenue beat(2)-1.58%
Min Revenue beat(2)-1.81%
Max Revenue beat(2)-1.36%
Revenue beat(4)1
Avg Revenue beat(4)0.44%
Min Revenue beat(4)-2.67%
Max Revenue beat(4)7.58%
Revenue beat(8)3
Avg Revenue beat(8)-0.1%
Revenue beat(12)4
Avg Revenue beat(12)-3.78%
Revenue beat(16)6
Avg Revenue beat(16)-3.51%
PT rev (1m)33.57%
PT rev (3m)33.57%
EPS NQ rev (1m)361.76%
EPS NQ rev (3m)361.76%
EPS NY rev (1m)103.63%
EPS NY rev (3m)103.63%
Revenue NQ rev (1m)3.01%
Revenue NQ rev (3m)3.01%
Revenue NY rev (1m)-5.03%
Revenue NY rev (3m)-5.03%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 18.65 | ||
| P/S | 11.35 | ||
| P/FCF | 3.75 | ||
| P/OCF | 3.74 | ||
| P/B | 3.92 | ||
| P/tB | 3.92 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.05
EYN/A
EPS(NY)0.96
Fwd EY5.36%
FCF(TTM)4.81
FCFY26.7%
OCF(TTM)4.81
OCFY26.72%
SpS1.59
BVpS4.59
TBVpS4.59
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.06% | ||
| ROE | 12.61% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 36.53% | ||
| GM | N/A | ||
| FCFM | 303.11% |
ROA(3y)37.73%
ROA(5y)0.15%
ROE(3y)46.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score9
Asset Turnover0.19
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.14 | ||
| Debt/FCF | 0.13 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | -13.08% | ||
| Cap/Sales | 0.28% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | 829.74% | ||
| Current Ratio | 9.48 | ||
| Quick Ratio | 9.48 | ||
| Altman-Z | 0.73 |
F-Score9
WACC9.34%
ROIC/WACCN/A
Cap/Depr(3y)53.03%
Cap/Depr(5y)62.83%
Cap/Sales(3y)1.99%
Cap/Sales(5y)4.27%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-10.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%126.92%
EPS Next Y275.95%
EPS Next 2Y69.86%
EPS Next 3Y27.47%
EPS Next 5Y29.13%
Revenue 1Y (TTM)27.12%
Revenue growth 3Y5.2%
Revenue growth 5Y-2.59%
Sales Q2Q%18.51%
Revenue Next Year71.87%
Revenue Next 2Y17.68%
Revenue Next 3Y24.7%
Revenue Next 5Y31.87%
EBIT growth 1Y16.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y259.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y262.26%
OCF growth 3YN/A
OCF growth 5YN/A
THERAVANCE BIOPHARMA INC / TBPH FAQ
What is the fundamental rating for TBPH stock?
ChartMill assigns a fundamental rating of 4 / 10 to TBPH.
Can you provide the valuation status for THERAVANCE BIOPHARMA INC?
ChartMill assigns a valuation rating of 4 / 10 to THERAVANCE BIOPHARMA INC (TBPH). This can be considered as Fairly Valued.
How profitable is THERAVANCE BIOPHARMA INC (TBPH) stock?
THERAVANCE BIOPHARMA INC (TBPH) has a profitability rating of 3 / 10.
How financially healthy is THERAVANCE BIOPHARMA INC?
The financial health rating of THERAVANCE BIOPHARMA INC (TBPH) is 6 / 10.
What is the expected EPS growth for THERAVANCE BIOPHARMA INC (TBPH) stock?
The Earnings per Share (EPS) of THERAVANCE BIOPHARMA INC (TBPH) is expected to grow by 275.95% in the next year.